Corvus Pharmaceuticals
CRVS
45 hedge funds and large institutions have $268M invested in Corvus Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
0% more funds holding
Funds holding: 45 → 45 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
5.11% less ownership
Funds ownership: 82.9% → 77.79% (-5.1%)
68% less capital inflows, than outflows
Capital inflows: $7.1M | Capital outflows: $22.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$2.79M |
| 2 |
Millennium Management
New York
|
+$1.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$771K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$532K |
| 5 |
State Street
Boston,
Massachusetts
|
+$368K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.86M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$285K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$184K |
| 5 |
JP Morgan Chase
New York
|
-$147K |
CRVS Hedge Fund Activity: Q3 2016 in Review
45 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2016, worth a combined $268M — up 13% from $237M a quarter earlier.
Fund positioning in CRVS was balanced in Q3 2016: 7 funds opened new positions, 7 closed out, 15 added to existing stakes and 10 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $2.79M. The largest seller was Fidelity Investments, cutting an estimated $18.5M.
- 45 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $268M of Corvus Pharmaceuticals stock for Q3 2016, up 13% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q3 2016 and 7 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2016 was Avoro Capital Advisors, an estimated $2.79M added.
- The largest Corvus Pharmaceuticals seller in Q3 2016 was Fidelity Investments, an estimated $18.5M sold.
Based on aggregated 13F filings for Q3 2016.